A US company has tested a brain implant in four Chinese patients in Shanghai, a rare sign of cooperation as the
The company, Axoft, also said this week that it raised $55 million. It’s tested its device temporarily in 11 patients, including the four in Shanghai. Axoft plans to study its device in more patients in China this year and is planning multiple clinical trials in the country, Chief Executive Officer Paul Le Floch said.
It’s the first time a US brain implant company has disclosed that it’s tested a device ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
